ARDX241101C7000
- 0.18
- +0.04+28.57%
Ardelyx Newsroom
Piper Sandler Maintains Ardelyx(ARDX.US) With Hold Rating, Maintains Target Price $7
Piper Sandler Maintains Ardelyx(ARDX.US) With Hold Rating, Maintains Target Price $7
Piper Sandler Remains a Hold on Ardelyx (ARDX)
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Ardelyx (ARDX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)
Ardelyx Analyst Ratings
HC Wainwright & Co. Maintains Buy on Ardelyx, Raises Price Target to $11
H.C. Wainwright Maintains Ardelyx(ARDX.US) With Buy Rating, Raises Target Price to $11
Ardelyx: Strong Sales Growth and Strategic Expansion Drive Buy Rating
Ardelyx Analyst Ratings
Wedbush Reiterates Outperform on Ardelyx, Maintains $11 Price Target
A Quick Look at Today's Ratings for Ardelyx(ARDX.US), With a Forecast Between $7 to $12
Ardelyx's Robust Drug Performance and Growth Potential Warrants a Buy Rating
Piper Sandler Gives a Hold Rating to Ardelyx (ARDX)
Piper Sandler Downgrades Ardelyx(ARDX.US) to Hold Rating, Cuts Target Price to $7
Piper Sandler Sticks to Their Hold Rating for Ardelyx (ARDX)
HC Wainwright & Co. Reiterates Buy on Ardelyx, Maintains $10 Price Target
Ardelyx Analyst Ratings
Wedbush Sticks to Its Buy Rating for Ardelyx (ARDX)
Ardelyx's Strategic Response to Regulatory Challenges: A High-Risk Buy Rating With Potential for Substantial Return